The estimated Net Worth of Karen Akinsanya is at least $681 mil dollars as of 15 October 2021. Dr Akinsanya owns over 1,393 units of Schrodinger stock worth over $28,668 and over the last 5 years he sold SDGR stock worth over $0. In addition, he makes $651,901 as Exec. VP e Chief Biomedical Scientist and Head of Discovery R&D at Schrodinger.
Dr has made over 7 trades of the Schrodinger stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,393 units of SDGR stock worth $6,046 on 15 October 2021.
The largest trade he's ever made was exercising 37,738 units of Schrodinger stock on 16 August 2021 worth over $404,174. On average, Dr trades about 7,836 units every 36 days since 2020. As of 15 October 2021 he still owns at least 1,393 units of Schrodinger stock.
You can see the complete history of Dr Akinsanya stock trades at the bottom of the page.
Dr. Karen Akinsanya Ph.D. is the Exec. VP, Chief Biomedical Scientist and Head of Discovery R&D at Schrodinger.
As the Exec. VP e Chief Biomedical Scientist and Head of Discovery R&D of Schrodinger, the total compensation of Dr D at Schrodinger is $651,901. There are 2 executives at Schrodinger getting paid more, with Dr. Ramy Farid Ph.D. having the highest compensation of $1,010,921.
Dr D is 53, he's been the Exec. VP e Chief Biomedical Scientist and Head of Discovery R&D of Schrodinger since . There are 11 older and 11 younger executives at Schrodinger. The oldest executive at Schrodinger, Inc. is Dr. Richard A. Friesner, 68, who is the Co-Founder, Scientific Advisory Chairman and Director.
Karen's mailing address filed with the SEC is C/O SCHRODINGER, INC.,, 1540 BROADWAY, 24TH FLOOR, NEW YORK, NY, 10036.
Over the last 5 years, insiders at Schrodinger have traded over $1,009,056,149 worth of Schrodinger stock and bought 838,235 units worth $14,249,995 . The most active insiders traders include & Melinda Gates Foundation ..., David E Schrodinger Equity ..., eMichael Lynton. On average, Schrodinger executives and independent directors trade stock every 10 days with the average trade being worth of $2,459,207. The most recent stock trade was executed by Kenneth Patrick Lorton on 6 March 2024, trading 5,574 units of SDGR stock currently worth $24,191.
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Schrodinger executives and other stock owners filed with the SEC include: